Investigation of urinary pteridine levels as potential biomarkers for noninvasive diagnosis of cancer.

BACKGROUND Biomarkers are good potential tools for early cancer diagnosis. Here we have analyzed eight different pteridines in the urine samples of cancer patients and compared them with samples from healthy subjects. Pteridines are important cofactors in the process of cell metabolism, and they have recently become a focal point of cancer screening research because certain pteridine levels have been shown to reflect the presence of cancers. METHODS We analyzed 8 pteridines; 6,7-dimethylpterin, 6-biopterin, d-(+)-neopterin, 6-hydroxymethylpterin, pterin, isoxanthopterin, xanthopterin and pterin-6-carboxylic acid using a house-built high-performance capillary electrophoresis with laser-induced fluorescence detection (HPCE-LIF). The levels of pteridines were reported as a ratio of pteridine to creatinine. Statistical hypothesis testing was conducted and P values were calculated to analyze the data. RESULTS Among the eight pteridines studied, 6-biopterin, 6-hydroxymethylpterin, pterin, xanthopterin, and isoxanthopterin levels were significantly higher in samples from cancer patients than in those from healthy subjects. Further, xanthopterin and isoxanthopterin levels were compared in breast cancer and lung cancer patients, but no significant difference was observed. CONCLUSION Some pteridine levels can be used as biomarkers for noninvasive diagnosis of cancer; however, more data is needed to support this hypothesis.

[1]  R. Smith,et al.  Urinary excretion levels of unconjugated pterins in cancer patients and normal individuals. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[2]  D. Fuchs,et al.  Neopterin as a marker for immune system activation. , 2002, Current drug metabolism.

[3]  Honglan Shi,et al.  A simple and fast method to determine and quantify urinary creatinine , 1995 .

[4]  G Reibnegger,et al.  Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. , 1989, Clinical chemistry.

[5]  B. H. Huynh,et al.  Pteridine analysis in urine by capillary electrophoresis using laser-induced fluorescence detection. , 1999, Analytical chemistry.

[6]  J. A. Halpern,et al.  Pterin-6-aldehyde, a cancer cell catabolite: identification and application in diagnosis and treatment of human cancer. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Yinfa Ma,et al.  Optimization of urinary pteridine analysis conditions by CE‐LIF for clinical use in early cancer detection , 2009, Electrophoresis.

[8]  J. Goedert,et al.  Neopterin and β2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection , 2005, Infection.

[9]  S. Kaufman.  THE STRUCTURE OF THE PHENYLALANINE-HYDROXYLATION COFACTOR. , 1962, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Tomandl,et al.  Determination of total oncopterin, neopterin and biopterin in human urine by high performance liquid chromatography with solid phase extraction , 2003 .

[11]  M. Hüfner,et al.  Pteridines in Cancer and Other Diseases , 1983 .

[12]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[13]  J. M. Noronha,et al.  A Rapid Assay for Urinary Pteridine Levels for Monitoring Cancer , 1993 .